p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsA strategy to study tyrosinase transgenes in mouse melanocytes.ARF functions as a melanoma tumor suppressor by inducing p53-independent senescenceThe relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.Transcriptional networks and cellular senescence in human mammary fibroblasts.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Markers of cellular senescence are elevated in murine blastocysts cultured in vitro: molecular consequences of culture in atmospheric oxygen.EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.Interferon-γ induces senescence in normal human melanocytes.Human melanocyte senescence and melanoma susceptibility genes.Pharmacogenetic candidate genes for melanoma.p16INK4a-induced senescence is disabled by melanoma-associated mutationsMelanomagenesis: overcoming the barrier of melanocyte senescence.The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems.Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging.Advances in melanoma senescence and potential clinical application.Oncogene-induced senescence and melanoma: where do we stand?Cyclin-dependent kinases as therapeutic targets in melanoma.Isolation, culture, and transfection of melanocytes.Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression.Genetics of melanoma progression: the rise and fall of cell senescence.A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgroundsDeciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.Alpha-MSH regulates intergenic splicing of MC1R and TUBB3 in human melanocytes.The T1796A mutation of the BRAF gene is absent in Spitz nevi.Cellular senescence in naevi and immortalisation in melanoma: a role for p16?Targeting oncogenic BRAF in human cancer.Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma PatientsRole of p16(INK4A) in Replicative Senescence and DNA Damage-Induced Premature Senescence in p53-Deficient Human Cells.Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.Pathways from senescence to melanoma: focus on MITF sumoylation.A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility.p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.Angiotropism and extravascular migratory metastasis in cutaneous and uveal melanoma progression in a zebrafish model.
P2860
Q21284811-2288430B-AB42-4700-9AE6-B863CD3E7CC9Q24792872-0D58DCD7-60B8-4466-B6B1-88F20FEBFC09Q28591778-75552D99-4CD3-436A-979D-7BBE8DA2C700Q33588743-927DAB9F-15EB-44B2-9D45-E2900D3E36C8Q33763939-8F416761-68A9-40AC-B260-C61DE17D7344Q33822119-9A2E4368-CD81-485B-A068-FB2C22B84E25Q34226393-9D577939-7A64-4B63-A3C4-C4CE667D5A4CQ34803805-974F47B1-31EF-454F-9C80-81F5256CBC6BQ35134926-6B6CA48B-33F3-48B4-95CA-72BDA3BFDA93Q35146545-20458CBF-000B-485E-99EE-467D22F9ED35Q35574952-C9F1BFD4-F5BA-4669-ABE1-B0DFA57FDB26Q36971412-C8AF3820-157E-40A6-8712-D974863CE093Q37182019-7A3EFA08-1230-43CF-B543-57E998A023CCQ37188584-14C77D85-71D3-43F5-9B6F-3DBA891A1831Q37535193-3D4E8762-9320-4823-B627-AB92C6867762Q37620888-591B3BA6-3A00-4884-A601-5668034B428CQ37818577-B9EC326E-1504-4937-9841-E44C12469A15Q37948288-1284CBCA-81EA-4961-BB53-5AB3F57F7921Q38177036-ECE5D418-117E-44D5-9EEA-19199AC710C1Q38217446-4FFB2AAA-8580-4198-BA74-8BE907865BC4Q38430876-07FC537D-90FA-463F-BE9C-8AD586C64728Q38589518-9C34DAFE-87B2-42B4-B513-B4B5E36F1DF9Q38694968-F613974E-26D9-478D-8756-AED66CF94041Q38708964-FBF3B8E6-7C32-4B35-A85B-94C497A2DA4EQ39181848-7A46CC75-C320-4F07-B8A8-FEEED564A75BQ39632902-0B391129-898F-47E9-9779-DB673AFC9322Q40529281-22F57E1D-3733-441B-8A57-0024D4D0CA04Q42016240-590BEFAB-DB3D-4A47-A046-37C26875C0E9Q42020468-38A70335-D790-40DC-8707-23A76B49DB0CQ42111608-490E9545-B735-4943-BE99-D4B19BD88BACQ42286334-4819BD73-EB5B-49A5-B4CF-506B6B7A7BB1Q42775021-72E23C97-01D2-44C6-85AF-6B51B4F43E19Q47224965-4F0B15F0-2F80-41C2-9C46-BA0E7AADD646Q47264647-5AEDFED1-CB3C-4477-B625-6B0DA7095834Q47927484-BCD3C23B-8707-40E6-AB24-132447DF0D55Q51686167-406D4612-147B-472D-9AE6-376577D095A1Q53126913-B6E4C8EF-FBDA-4ACE-961E-FCDAB6BE0D33Q55645366-3E310191-9542-46EF-AE8E-301C66B3A462
P2860
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
p16/cyclin-dependent kinase in ...... ions for melanoma progression.
@en
type
label
p16/cyclin-dependent kinase in ...... ions for melanoma progression.
@en
prefLabel
p16/cyclin-dependent kinase in ...... ions for melanoma progression.
@en
P2093
P2860
P356
P1476
p16/cyclin-dependent kinase in ...... tions for melanoma progression
@en
P2093
David Kipling
David Wynford-Thomas
Dorothy C Bennett
Elena V Sviderskaya
Gordon Peters
Simon P Hill
Tracy J Evans-Whipp
Vanessa C Gray-Schopfer
P2860
P304
P356
10.1093/JNCI/95.10.723
P407
P50
P577
2003-05-01T00:00:00Z